Drugs / TolueneSulfonamide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07332858 | Apr 2026 → Oct 2028 expected | non-small cell lung carcinoma, pleural neoplasm | Gang Hou | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06607796 | Mar 2024 → Dec 2026 expected | lung cancer | Zhou Chengzhi | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Toluenesulfonamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06607796 ↗ |
| Known as | PTS | “Toluenesulfonamide (PTS) Intratumoral Injection” NCT06607796 ↗ |
| Route | Other | “intrapleural injection of TolueneSulfonamide” NCT07332858 ↗ |